Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765319000015/mck10q06302019.htm
May 2022
April 2022
April 2022
February 2022
February 2022
February 2022
January 2022
November 2021
October 2021
September 2021
Exhibit 99.1
McKESSON REPORTS FISCAL 2020 FIRST-QUARTER RESULTS
| First-quarter fiscal 2020 revenues of $55.7 billion, an increase of 6%. |
| First-quarter GAAP earnings per diluted share from continuing operations of $2.27, up 429% year over year. |
| First-quarter Adjusted Earnings per diluted share of $3.31, up 14% year over year. |
| Raised fiscal 2020 Adjusted EPS guidance range to $14.00 to $14.60 from $13.85 to $14.45. |
| Board of Directors increased the quarterly dividend by 5% to 41 cents per share. |
IRVING, Texas, July 31, 2019 McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2019, were $55.7 billion compared to $52.6 billion a year ago, an increase of 6% on a reported basis and an increase of 7% on an FX-adjusted basis.
On the basis of U.S. generally accepted accounting principles (GAAP), first-quarter earnings per diluted share from continuing operations was $2.27, compared to a loss per diluted share of $(0.69) a year ago.
First-quarter Adjusted Earnings per diluted share was $3.31, an increase of 14% compared to $2.90 a year ago, primarily driven by growth in the U.S. Pharmaceutical and Specialty Solutions segment and a lower share count, partially offset by a higher tax rate.
McKesson is off to a strong start in fiscal 2020, and our first-quarter earnings performance exceeded our expectations, said Brian Tyler, chief executive officer. Based on the momentum from our first-quarter results and our confidence in the full year outlook, we are raising our previous guidance range for fiscal 2020 and now expect Adjusted Earnings per diluted share of $14.00 to $14.60.
1
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765319000015/mck10q06302019.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Mckesson Corp.
Mckesson Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
European Pharmaceutical Solutions: Operating profit and operating profit margin increased for the first quarter of 2020 compared to the same period a year ago primarily due to the 2019 goodwill impairment charges of $570 million and lower restructuring and asset impairment charges, partially offset by continuous lower government reimbursements in the U.K. Operating profit in in the first quarter of 2020 was also unfavorably impacted by lower sales volume in retail pharmacy U.K. Medical-Surgical Solutions: Operating profit for this segment increased for the first quarter of 2020 compared to the same period a year ago primarily due to market growth.
Gross profit and gross profit margin for 2020 were also unfavorably affected by continuous lower government reimbursements in the United Kingdom ("U.K.") and lower last-in, first-out ("LIFO") credits.
Operating profit margin slightly decreased primarily due to the 2019 net cash proceeds representing our share of antitrust legal settlements and lower LIFO credits, partially offset by lower opioid-related costs.
Refer to Financial Note 15, "Commitments and Contingent Liabilities," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q; First quarter 2019 pre-tax restructuring and asset impairment charges of $96 million ($85 million after-tax), primarily representing employee severance, exit-related costs and asset impairment charges; and First quarter 2019 gain from an escrow settlement of $97 million (pre-tax and after-tax) representing certain indemnity and other claims related to our third quarter 2017 acquisition of Rexall Health.
However, other risks, expenses and future developments, such as additional government actions and material changes in key market assumptions that we were unable to anticipate as of the 2019 testing date may require us to revise the projected cash flows, which could adversely affect the fair value of our McKesson Canada reporting unit in Other in future periods.
Corporate: Corporate expenses, net, increased...Read more
Restructuring Initiatives During 2019, we...Read more
Upon the effectiveness of the...Read more
Operating Expenses Operating expenses, and...Read more
The Company's Board has authorized...Read more
Gross profit margin decreased in...Read more
European Pharmaceutical Solutions European Pharmaceutical...Read more
Operating activities for the first...Read more
38 38 Table of ContentsMcKESSON...Read more
In addition, certain states have...Read more
Amortization Expenses of Acquired Intangible...Read more
Additionally, operating expenses decreased due...Read more
Segment Operating Profit U.S. Pharmaceutical...Read more
New Accounting Pronouncements New accounting...Read more
We are subject to legal...Read more
In connection with these initiatives,...Read more
The first quarter of 2019...Read more
Net Income (Loss) Attributable to...Read more
Segment Results: Revenues: U.S. Pharmaceutical...Read more
The reader should not consider...Read more
Changes in the Canadian healthcare...Read more
Any significant changes in assumptions...Read more
As of June 30, 2019,...Read more
However, there can be no...Read more
The State of New York...Read more
Revenues decreased primarily due to...Read more
33 33 Table of ContentsMcKESSON...Read more
The redemption value is the...Read more
Changes to any of the...Read more
Tax legislation initiatives or challenges...Read more
We could experience losses or...Read more
40 40 Table of ContentsMcKESSON...Read more
44 44 Table of ContentsMcKESSON...Read more
Our future results could be...Read more
We believe that our operating...Read more
Changes in accounting standards issued...Read more
Medical-Surgical Solutions Medical-Surgical Solutions revenues...Read more
On July 1, 2019, upon...Read more
Financing activities for the first...Read more
Changes in the European regulatory...Read more
Other Revenues in Other decreased...Read more
In addition, from time to...Read more
Additionally, we committed to certain...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Mckesson Corp provided additional information to their SEC Filing as exhibits
Ticker: MCK
CIK: 927653
Form Type: 10-Q Quarterly Report
Accession Number: 0000927653-19-000015
Submitted to the SEC: Wed Jul 31 2019 2:13:10 PM EST
Accepted by the SEC: Thu Aug 01 2019
Period: Sunday, June 30, 2019
Industry: Wholesale Drugs Proprietaries And Druggists Sundries